An in Vitro deletion in ribE encoding lumazine synthase contributes to nitrofurantoin resistance in Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7225-7233

  Vervoort, Jascha ^a   Xavier, Basil Britto ^a   Stewardson, Andrew ^b,c   Coenen, Samuel ^a   Godycki Cwirko, Maciek ^d   Adriaenssens, Niels ^a   Kowalczyk, Anna ^d   Lammens, Christine ^a   Harbarth, Stephan ^b   Goossens, Herman ^a   Malhotra Kumar, Surbhi ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CEFUROXIME; CIPROFLOXACIN; FLAVINE MONONUCLEOTIDE; LUMAZINE SYNTHASE RIBE; NITROFURANTOIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SYNTHETASE; UNCLASSIFIED DRUG; 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE; ANTIINFECTIVE AGENT; ESCHERICHIA COLI PROTEIN; MULTIENZYME COMPLEX; NFSA PROTEIN, E COLI; NFSB PROTEIN, E COLI; NITROREDUCTASE; QUINOLONE DERIVATIVE; RIBOFLAVIN SYNTHASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ESCHERICHIA COLI; FECES; FECES MICROFLORA; GENE DELETION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; URINARY TRACT INFECTION; AEROBIC METABOLISM; ANAEROBIC GROWTH; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI INFECTIONS; GENETIC COMPLEMENTATION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR GENETICS; URINARY TRACT INFECTIONS;

AEROBIOSIS; ANAEROBIOSIS; ANTI-BACTERIAL AGENTS; BASE SEQUENCE; CEFUROXIME; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; GENETIC COMPLEMENTATION TEST; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MULTIENZYME COMPLEXES; NITROFURANTOIN; NITROREDUCTASES; RIBOFLAVIN SYNTHASE; SEQUENCE DELETION; URINARY TRACT INFECTIONS;

EID: 84912533203     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03952-14     Document Type: Article

References (33)

1. Shah RR, Wade G. 1989. Reappraisal of the risk/benefit of nitrofurantoin: review of toxicity and efficacy. Adverse Drug React. Acute Poisoning Rev. 8:183-201.
2. Conklin JD. 1978. The pharmacokinetics of nitrofurantoin and its related bioavailability. Antibiot. Chemother. 25:233-252.
3. Guay DR. 2001. An update on the role of nitrofurans in the management of urinary tract infections. Drugs 61:353-364. http://dx.doi.org/10.2165 /00003495-200161030-00004.
4. McOsker CC, Fitzpatrick PM. 1994. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J. Antimicrob. Chemother. 33(Suppl A):23-30.
5. Whiteway J, Koziarz P, Veall J, Sandhu N, Kumar P, Hoecher B, Lambert IB. 1998. Oxygen-insensitive nitroreductases: analysis of the roles of nfsA and nfsB in development of resistance to 5-nitrofuran derivatives in Escherichia coli. J. Bacteriol. 180:5529-5539.
6. McCalla DR, Kaiser C, Green MH. 1978. Genetics of nitrofurazone resistance in Escherichia coli. J. Bacteriol. 133:10-16.
7. Sandegren L, Lindqvist A, Kahlmeter G, Andersson DI. 2008. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J. Antimicrob. Chemother. 62:495-503. http://dx.doi.org/10.1093/jac/dkn222.
8. Rafii F, Hansen EB, Jr. 1998. Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob. Agents Chemother. 42:1121-1126.
9. Calva JJ, Sifuentes-Osornio J, Ceron C. 1996. Antimicrobial resistance in fecal flora: longitudinal community-based surveillance of children from urban Mexico. Antimicrob. Agents Chemother. 40:1699-1702.
10. London N, Nijsten R, van der Bogaard A, Stobberingh E. 1994. Carriage of antibiotic-resistant Escherichia coli by healthy volunteers during a 15- week period. Infection 22:187-192. http://dx.doi.org/10.1007/BF0171 6700.
11. Stamey TA, Condy M, Mihara G. 1977. Prophylactic efficacy of nitrofurantoin macrocrystals and trimethoprim-sulfamethoxazole in urinary infections: biologic effects on the vaginal and rectal flora. N. Engl. J. Med. 296:780-783.
12. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Xavier BB, Vervoort J, Stewardson A, Adriaenssens N, Coenen S, Harbarth S, Goossens H, Malhotra-Kumar S. 2014. Complete genome sequences of nitrofurantoin-sensitive and -resistant Escherichia coli ST540 and ST2747 strains. Genome Announc. 2:e00239-14. http://dx.doi.org/10 .1128/genomeA.00239-14.
14. Darling AC, Mau B, Blattner FR, Perna NT. 2004. Mauve: multiple alignment of conserved genomic sequence with rearrangements. Genome Res. 14:1394-1403. http://dx.doi.org/10.1101/gr.2289704.
15. Kurtz S, Phillippy A, Delcher AL, Smoot M, Shumway M, Antonescu C, Salzberg SL. 2004. Versatile and open software for comparing large genomes. Genome Biol. 5:R12. http://dx.doi.org/10.1186/gb-2004-5-2-r12.
16. Mortl S, Fischer M, Richter G, Tack J, Weinkauf S, Bacher A. 1996. Biosynthesis of riboflavin: lumazine synthase of Escherichia coli. J. Biol. Chem. 271:33201-33207.
17. Kidwell MG, Lisch DR. 2000. Transposable elements and host genome evolution. Trends Ecol. Evol. 15:95-99. http://dx.doi.org/10.1016/S0169 -5347(99)01817-0.
18. Martinez JL, Baquero F. 2000. Mutation frequencies and antibiotic resistance. Antimicrob. Agents Chemother. 44:1771-1777. http://dx.doi.org /10.1128/AAC.44.7.1771-1777.2000.
19. Peterson FJ, Mason RP, Hovsepian J, Holtzman JL. 1979. Oxygensensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. J. Biol. Chem. 254:4009-4014.
20. Marques de Oliveira I, Bonatto D, Pêgas Henriques JA. 2010. Nitroreductases: enzymes with environmental, biotechnological and clinical importance, p 1008-1019. In Mendez-Vilas A (ed), Current research, technology and education topics in applied microbiology and microbial biotechnology, vol 2 Formatex Research Center, Badajoz, Spain.
21. Mercier C, Chalansonnet V, Orenga S, Gilbert C. 2013. Characteristics of major Escherichia coli reductases involved in aerobic nitro and azo reduction. J. Appl. Microbiol. 115:1012-1022. http://dx.doi.org/10.1111 /jam.12294.
22. Ladenstein R, Schneider M, Huber R, Bartunik HD, Wilson K, Schott K, Bacher A. 1988. Heavy riboflavin synthase from Bacillus subtilis: crystal structure analysis of the icosahedral 60 capsid at 3.3 Å resolution. J. Mol. Biol. 203:1045-1070.
23. Ritsert K, Huber R, Turk D, Ladenstein R, Schmidt-Base K, Bacher A. 1995. Studies on the lumazine synthase/riboflavin synthase complex of Bacillus subtilis: crystal structure analysis of reconstituted, icosahedral subunit capsids with bound substrate analogue inhibitor at 2.4 Å resolution. J. Mol. Biol. 253:151-167. http://dx.doi.org/10.1006/jmbi.1995 .0542.
24. Zenno S, Koike H, Kumar AN, Jayaraman R, Tanokura M, Saigo K. 1996. Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J. Bacteriol. 178:4508-4514.
25. Fischer M, Bacher A. 2008. Biosynthesis of vitamin B2: structure and mechanism of riboflavin synthase. Arch. Biochem. Biophys. 474:252-265. http://dx.doi.org/10.1016/j.abb.2008.02.008.
26. Vogl C, Grill S, Schilling O, Stulke J, Mack M, Stolz J. 2007. Characterization of riboflavin (vitamin B2) transport proteins from Bacillus subtilis and Corynebacterium glutamicum. J. Bacteriol. 189:7367-7375. http: //dx.doi.org/10.1128/JB.00590-07.
27. Fraaije MW, Mattevi A. 2000. Flavoenzymes: diverse catalysts with recurrent features. Trends Biochem. Sci. 25:126-132. http://dx.doi.org/10 .1016/S0968-0004(99)01533-9.
28. Lee N, Bendet I. 1967. Crystalline L-ribulokinase from Escherichia coli. J. Biol. Chem. 242:2043-2050.
29. Shimada T, Kori A, Ishihama A. 2013. Involvement of the ribose operon repressor RbsR in regulation of purine nucleotide synthesis in Escherichia coli. FEMS Microbiol. Lett. 344:159-165. http://dx.doi.org/10.1111/1574 -6968.12172.
30. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8:260-271. http://dx .doi.org/10.1038/nrmicro2319.
31. Poulsen HO, Johansson A, Granholm S, Kahlmeter G, Sundqvist M. 2013. High genetic diversity of nitrofurantoin- or mecillinam-resistant Escherichia coli indicates low propensity for clonal spread. J. Antimicrob. Chemother. 68:1974-1977. http://dx.doi.org/10.1093/jac/dkt159.
32. Van Heirstraeten L, Coenen S, Lammens C, Hens N, Goossens H, Malhotra-Kumar S. 2012. Antimicrobial drug use and macrolideresistant Streptococcus pyogenes, Belgium. Emerg. Infect. Dis. 18:1515-1518. http://dx.doi.org/10.3201/eid1809.120049.
33. Andersson DI, Levin BR. 1999. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2:489 -493. http://dx.doi.org/10.1016 /S1369-5274(99)00005-3.